Background The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the
incidence of major adverse cardiovascular events when administered at hospital admission …

Background—Aspirin and clopidogrel are recommended for patients with acute coronary
syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12 …

Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in
patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous …

Background Current guidelines recommend intensified platelet inhibition by prasugrel or
ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) …

Background—Ticagrelor and prasugrel provide stronger platelet inhibition compared with
clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported …

Background: No randomized head-to-head comparison of the efficacy and safety of
ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these …

Background The relative merits of ticagrelor as compared with prasugrel in patients with
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …

BACKGROUND: Antiplatelet therapy is essential treatment for acute coronary syndromes
(ACS). Current therapies, however, have important limitations affecting their clinical success …

Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine
diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet …

Background: Owing to the differential propensity for bleeding and ischemic events with
response to antiplatelet therapy, the safety and effectiveness of potent P2Y12 inhibitor …